AstraZeneca (AZN) Stock Edges Higher Despite Discontinuing Phase III Lung Cancer Study
TLDR The pharmaceutical company has pulled the plug on its Phase III eVOLVE-Lung02 study evaluating volrustomig combined with chemotherapy for metastatic non-small cell lung cancer A data mon





